Immune-mediated inflammatory disease patients’ preferences in adverse drug reaction information regarding biologics

Autor: Eugène van Puijenbroek, Frank Hoentjen, Phyllis I. Spuls, Martijn B. A. van Doorn, Bart J F van den Bemt, Michael T. Nurmohamed, G. Weits, L. Kosse, Naomi T Jessurun, Harald E. Vonkeman, Sander W. Tas

Publikováno v: Expert Opinion on Drug Safety, 19, 8, pp. 1049-1054
Expert Opinion on Drug Safety, 19(8), 1049-1054. Taylor & Francis Ltd
Expert opinion on drug safety, 19(8), 1049-1054. Taylor & Francis
Kosse, L J, Weits, G, Vonkeman, H E, Spuls, P I, Van Den Bemt, B J F, Tas, S W, Hoentjen, F, Nurmohamed, M T, Van Doorn, M B A, Van Puijenbroek, E P & Jessurun, N T 2020, ' Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics ', Expert opinion on drug safety, vol. 19, no. 8, pp. 1049-1054 . https://doi.org/10.1080/14740338.2020.1781090
Expert Opinion on Drug Safety, 19, 1049-1054
Expert opinion on drug safety, 19(8), 1049-1054. Taylor and Francis Ltd.
Expert opinion on drug safety, 1-5. Taylor and Francis Ltd.
STARTPAGE=1;ENDPAGE=5;ISSN=1474-0338;TITLE=Expert opinion on drug safety

OBJECTIVES: Patient-reported outcomes (PROs) are increasingly used in studies and medical practice to obtain information on patients' perspectives toward their treatment or disease. However, most study outcomes are primarily directed at healthcare pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d526eba6c4953f10dc4074834d38b923
https://doi.org/10.1080/14740338.2020.1781090

POS0271-HPR PATIENT PERSPECTIVE ON A DRUG SAFETY MONITORING SYSTEM FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES BASED ON PATIENT-REPORTED OUTCOMES

Autor: Geert R. D'Haens, B. van den Bemt, Phyllis I. Spuls, Frank Hoentjen, Naomi T Jessurun, Harald E. Vonkeman, G. Weits, E P van Puijenbroek, Michael T. Nurmohamed, Sander W. Tas, L. Kosse, M.B.A. van Doorn

Publikováno v: Annals of the Rheumatic Diseases. 80:359.2-359

Background:Patient-reported outcomes (PROs) on adverse drug reactions (ADRs) are increasingly used in cohort event monitoring (CEM) to obtain a better understanding of patient’s real-world experience with drugs. Despite the leading role for patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::11c0f7a64d5dbd66a992f4e589e98211
https://doi.org/10.1136/annrheumdis-2021-eular.635

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

Autor: J. M. Vicencio, R. Evans, R. Green, Z. An, J. Deng, C. Treacy, R. Mustapha, J. Monypenny, C. Costoya, K. Lawler, K. Ng, K. De-Souza, O. Coban, V. Gomez, J. Clancy, S. H. Chen, A. Chalk, F. Wong, P. Gordon, C. Savage, C. Gomes, T. Pan, G. Alfano, L. Dolcetti, J. N. E. Chan, F. Flores-Borja, P. R. Barber, G. Weitsman, D. Sosnowska, E. Capone, S. Iacobelli, D. Hochhauser, J. A. Hartley, M. Parsons, J. N. Arnold, S. Ameer-Beg, S. A. Quezada, Y. Yarden, G. Sala, T. Ng

Publikováno v: Cell Death and Disease, Vol 13, Iss 3, Pp 1-14 (2022)

Abstract Over the past decade, immunotherapy delivered novel treatments for many cancer types. However, lung cancer still leads cancer mortality, and non-small-cell lung carcinoma patients with mutant EGFR cannot benefit from checkpoint inhibitors du

Externí odkaz: https://doaj.org/article/74a9c9affa844590bf23f0789ca9a0fd

Generating optimal signal positions

Autor: E. A. G. Weits, D. van de Weijenberg

Publikováno v: WIT Transactions on The Built Environment.

This paper on generating optimal signal positions is from the proceedings of the 12th International Conference on Computer System Design and Operation in Railways and Other Transit Systems, held in Beijing, China, in 2010. In The Netherlands railway

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ceafd5192de61684bc98527bba2bf06
https://doi.org/10.2495/cr100291

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.